
Although medical progress is allowing us to treat more and more diseases, innovative medicines tend to be expensive. Expenses are rising constantly in the healthcare sector as a result, putting accessibility and affordability under pressure. Which criteria does the Belgian Commission for Reimbursement of Medicines apply and what could be improved? These questions are answered in a study based on RIZIV data, in the framework of the Roche Chair at the Vlerick Healthcare Management Centre.